Learning to Walk with COVID-19
A Case Report on COVID-19 Associated Guillain-Barre Syndrome

Benton Huang, M.D., Nishant Sharma, M.D., Syed Raza Ali Shah, M.D.
Northwest Washington Family Medicine Residency, Bremerton, WA

INTRODUCTION

● Guillain-Barre Syndrome (GBS) is a rare life threatening autoimmune polyneuropathy characterized by distal bilateral lower extremity weakness which ascends progressively to involve the upper limbs
● Pathogenesis involves a recent infectious etiology that triggers an autoimmune response targeting peripheral nerves and spinal roots.
● Recent data has suggested a correlation between COVID-19 and GBS.

CASE PRESENTATION

● 37 year old healthy female with past medical history of COVID-19 infection 4 months prior was admitted for bilateral symmetrical weakness with numbness and tingling sensations in both lower and upper extremities for 2 months
● Her physical exam revealed upper and lower extremity numbness in a glove-stocking pattern, 4/5 upper and lower extremity strength, and absent knee and ankle DTRs.
● CSF analysis showed albuminocytologic dissociation with elevated protein levels of 115 with normal WBC count.
● Additional workup including serum tests of Vitamin B12, folic acid, TSH, A1c, CK, HIV, heavy metals, SPEP were all normal.

DISCUSSION

● COVID-19 preceding GBS has been increasingly more reported.
● Clinical presentation is classically presented with progressive weakness and sensory symptoms in arms and legs, and in severe cases, phrenic nerve involvement causing respiratory failure.
● Our patient was diagnosed with GBS clinically based on her sensory deficits, areflexia, and weakness and by the presence of albuminocytologic dissociation present in CSF analysis.
● Average time between COVID-19 and onset of GBS symptoms is between 5-10 days
● Our patient’s delay may in part be due to “Post-Acute Sequelae of COVID-19 infection”, a phenomenon which is currently poorly understood

CONCLUSION

This case report highlights the importance of considering GBS as an important differential in patients with prior COVID-19 infection who present with sensorimotor symptoms for early diagnosis and treatment.

REFERENCES